InforSense has announced that Celera Corporation, a healthcare business delivering personalised disease management through a combination of products and services incorporating proprietary discoveries, is using InforSense to integrate internal molecular and public data sources to accelerate the successful identification of genetic markers, such as those Celera has reported for increased risk of Coronary Heart Disease (CHD).
The InforSense Translational Research Solution enables Celera to accelerate and automate many aspects of experimental data analysis and molecular annotation, saving considerable time and effort. Celera and InforSense have developed a long-term relationship that covers the use of InforSense's Translational Research Solution to glean insight from available data and inform follow up studies for diagnostic markers of disease at Celera. These collaborative efforts complement and extend the pioneering informatics efforts of both companies independently.
InforSense has provided Celera with a configurable, scientist-friendly solution for translational research to support clinical data browsing, automated integration and analysis of enzyme linked immunoassay (ELISA), single nucleotide polymorphisms (SNPs) and other experimental proprietary and public data. By building bioinformatic queries and statistical analysis workflows, waiting times for scientists are significantly reduced and further investigation can focus on innovative developments saving valuable time and reducing costs. Celera used the knowledge gained from the identification of the gene variant in KIF6 that predicts CHD, to create and assemble key workflows, which streamline the overall process and provide for future acceleration of discovery efforts of this and other markers.
'A commercialisation focus at Celera is developing advanced diagnostic biomarkers to detect, predict, characterise, monitor and select treatment for disease. We wanted to empower our scientists to be able to access and analyse a variety of orthologous clinical and experimental data to support biomarker discovery and InforSense has provided us with the means to do this,'said John Sninsky, vice president for research at Celera. 'Fundamental contributions were made to disease understanding through InforSense solutions prioritising literature queries and informing functional studies. Without these informatics tools, follow-up studies of gene variants would be delayed.'
